Últimas noticias sobre MediWound (NASDAQ:MDWD) Bolsa

MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

MediWound Ltd

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $215 to $230. Needham analyst Mike Cikos maintained a Buy rating. Snowflake shares closed at $179.12 on Wednesday. S<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) from $25 to $31. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. MediWound shares closed at $19.89 on Wednesday. <a href="https://www.benzinga.com/quote/MDWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) price target from $63 to $78. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Urban Outfitters shares closed at $59.60 on Wednesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased the price target for nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from $28 to $33. Needham analyst Mayank Tandon maintained a Buy rating. nCino shares closed at $25.48 on Wednesday. <a href="https://www.benzinga.com/quote/NCNO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup aslashed the price target for Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from $217 to $185. Citigroup analyst Joanna Wiensch downgraded the stock from Buy to Neutral. Becton, Dickinson shares closed at $173.14 on Wednesday. <a href="https://www.benzinga.com/quote/BDX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) price target from $13 to $8. Wedbush analyst Laura Chico downgraded the stock from Outperform to Neutral. Vigil Neuroscience shares settled at $2.31 on Wednesday. <a href="https://www.benzinga.com/quote/VIGL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised Integer Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) price target from $133 to $140. Citigroup analyst Joanne Wuensch upgraded the stock from Neutral to Buy. Integer Holdings shares closed at $118.88 on Wednesday. <a href="https://www.benzinga.com/quote/ITGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) price target from $90 to $100. Rosenblatt analyst Catharine Trebnick maintained a Buy rating. Zoom shares closed at $82.27 on Wednesday.  <a href="https://www.benzinga.com/quote/CM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased the price target for Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) from $4 to $6. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Navitas Semiconductor shares settled at $1.91 on Wednesday. <a href="https://www.benzinga.com/quote/NVTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) price target from $390 to $395. UBS analyst Kevin Mcveigh maintained a Buy rating. Accenture shares closed at $317.72 on Wednesday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ACN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-1024x586.png" alt="" class="wp-image-924453" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22091541/image-287.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

News

Price Target

Markets

Trading Ideas

ITGR

MDWD

NCNO

NVTS

SNOW

URBN

VIGL

Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and raises the price target from $25 to $31.

Analyst Ratings

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $31

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) sees FY2025 sales of $24.000 million vs $23.97 million analyst estimate.

Guidance

MediWound Sees FY2025 Sales $24.000M vs $23.97M Est

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.66) by 89.39 percent. This is a 82.05 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $3.96 million which missed the analyst consensus estimate of $5.20 million by 23.91 percent. This is a 20.33 percent decrease over sales of $4.96 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

MediWound Q1 EPS $(0.07) Beats $(0.66) Estimate, Sales $3.96M Miss $5.20M Estimate

<h3>Companies Reporting Before The Bell</h3>
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is likely to report quarterly loss at $0.66 per share on revenue of $5.20 million. 
• Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $262.86 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is projected to report quarterly loss at $0.04 per share on revenue of $18.20 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $973.69 million. 
• TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $13.03 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $8.83 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $1.65 per share on revenue of $24.35 billion. 
• Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is likely to report quarterly earnings at $2.88 per share on revenue of $20.97 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $4.30 billion. 
• Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $366.75 million. 
• CMB.Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMBT#NYSE">CMBT</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $224.00 million. 
• Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) is projected to report quarterly loss at $0.15 per share on revenue of $106.48 million. 
• Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) is projected to report quarterly earnings at $1.66 per share on revenue of $471.83 million. 
• Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $88.17 million. 
• Cool Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NYSE">CLCO</a>) is estimated to report earnings for its first quarter. 
• Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) is projected to report quarterly earnings at $1.62 per share on revenue of $1.19 billion. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is likely to report earnings for its first quarter. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is projected to report quarterly loss at $0.73 per share on revenue of $4.00 million. 
• WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) is likely to report earnings for its first quarter. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is projected to report earnings for its first quarter. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is likely to report earnings for its first quarter. 
• VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $2.17 billion. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $394.21 million. 
<h3>Companies Reporting After The Bell</h3>
• LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $185.41 million. 
• Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is projected to report quarterly earnings at $0.47 per share on revenue of $708.59 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.31 per share on revenue of $1.17 billion. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $1.29 billion. 
• American Superconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $60.27 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is likely to report earnings for its first quarter. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is likely to report quarterly loss at $0.19 per share on revenue of $77.75 million. 
• ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) is projected to report earnings for its first quarter. 
• Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $1.01 billion. 
• EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) is projected to report quarterly earnings at $2.55 per share on revenue of $1.02 billion. 
• Borr Drilling (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) is likely to report quarterly loss at $0.03 per share on revenue of $231.17 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMSC

BBAR

BIDU

BORR

BZUN

CLCO

CLIR

CMBT

DOMO

EVGN

FLNG

GOGL

GOOS

RAMP

XPEV

Earnings Scheduled For May 21, 2025

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-21. Here's what investors need to know before the announcement.
Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.64. 
MediWound bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.25, leading to a 6.73% drop in the share price on the subsequent day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.61</td>
<td>-0.44</td>
<td>-0.44</td>
<td>-0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.36</td>
<td>-0.98</td>
<td>-0.68</td>
<td>-0.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>3.0%</td>
<td>4.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747753342_0.png" alt="eps graph" />
<h3>Tracking MediWound's Stock Performance</h3>
Shares of MediWound were trading at $20.51 as of May 19. Over the last 52-week period, shares are up 17.83%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For MediWound

MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx&#xAE; compared with collagenase ointment (SANTYL&#xAE;), the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers.
The <a href="https://www.globenewswire.com/Tracker?data=vcrrKBu20hKK41Ce5bD1qXRUThIWpZnX_wY720Hfad0wLiA7Ub_KbJaTTTjNidGLW8d_D5w3ermEL3uFNM6iOsRsyz8VoL24c26uHXW4Xl2fOAQFBQP54IUifi1oAgLgwjfnwxfv2_9lrthX3c4vqyOG5WA4eX-Kbf1Uk1hQ-1yn8YXcGKYUyF83bUYscuz_FI-wxi3lsn8FDOHJf88SCLbLaQDBp1N-81MHio7zfjE=">article</a>, titled "Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of the ChronEx Trial," appears in the April 2025 edition of Wounds (Index 2025;37(4):166–173) and compares outcomes in a subgroup of patients from the non-surgical standard of care arm treated with SANTYL (n=8) to those treated with EscharEx (n=46).
"These new findings are consistent with my prior experience using EscharEx in clinical trials and SANTYL in clinical practice," said Dr. Cyaandi Dove, DPM, of the University of Texas Health Science Center at San Antonio and co-author of the publication. "Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. EscharEx's enzymatic formulation targets a wider range of non-viable and necrotic tissue, which may account for the favorable clinical outcomes observed."
Key findings from the post hoc analysis include:
<ul>
<li>Debridement Efficacy:
<ul>
<li>Complete debridement at 2 weeks was achieved in 63% of EscharEx-treated patients, compared to 0% in the SANTYL group (p = 0.001).</li>
<li>Median time to debridement was 9 days for EscharEx vs. not achieved for SANTYL (p = 0.023).</li>
</ul>
</li>
<li>Wound Bed Preparation (WBP):
<ul>
<li>WBP—defined as complete debridement and complete granulation—was achieved by 50% of EscharEx patients in 2 weeks vs. 0% with SANTYL (p = 0.015).</li>
<li>Over the entire study period (12 weeks), 78% of EscharEx patients achieved WBP vs. 38% with SANTYL (p = 0.03).</li>
<li>Median time to WBP: 11 days for EscharEx; not achieved for SANTYL (p = 0.014).</li>
</ul>
</li>
<li>Wound Closure:
<ul>
<li>Closure was achieved in 33% of EscharEx patients vs. 25% with SANTYL (not statistically significant).</li>
<li>Among those who closed, the mean time to closure was 48 days for EscharEx vs. 76 days with SANTYL (p = 0.05).</li>
</ul>
</li>
<li>Safety and Tolerability:
<ul>
<li>Adverse event rates and applicational pain were similar between groups.</li>
<li>Deep wound infection, assessed using recognized clinical criteria, occurred in 11% of EscharEx patients compared to 38% in the SANTYL group.</li>
</ul>
</li>
</ul>

MediWound's EscharEx Outperforms SANTYL in Healing Venous Leg Ulcers, Study Shows

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $25 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $25 Price Target

Health Care

General

MediWound Expects 2025 Sales Of $25M Versus Consensus Of $24.98M

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.59) by 38.98 percent. This is a 89.47 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $5.84 million which beat the analyst consensus estimate of $5.75 million by 1.60 percent. This is a 9.40 percent increase over sales of $5.34 million the same period last year.

MediWound Q4 2024 GAAP EPS $(0.36) Beats $(0.59) Estimate, Sales $5.84M Beat $5.75M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Corporacion America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAAP#NYSE">CAAP</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $373.00 million. 
• Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) is likely to report quarterly earnings at $1.19 per share on revenue of $674.52 million. 
• Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $294.60 million. 
• GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $430.70 million. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is estimated to report quarterly loss at $0.61 per share on revenue of $5.75 million. 
• Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is expected to report quarterly earnings at $6.25 per share on revenue of $2.33 billion. 
• J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $142.33 million. 
• Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million. 
• Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is projected to report quarterly loss at $0.11 per share on revenue of $269.59 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is estimated to report earnings for its fourth quarter. 
• Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $747.94 million. 
• Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) is projected to report quarterly earnings at $2.93 per share on revenue of $2.35 billion. 
• General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $4.96 billion. 
• One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $15.00 million. 
• Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#NYSE">CWEB</a>) is estimated to report earnings for its fourth quarter. 
• HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) is expected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) is projected to report quarterly earnings at $3.38 per share on revenue of $1.38 billion. 
• Epsilon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSN#NASDAQ">EPSN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $7.22 million. 
• Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) is likely to report earnings for its fourth quarter. 
• TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $47.78 million. 
• Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $1.30 million. 
• SWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKH#NASDAQ">SWKH</a>) is expected to report quarterly earnings at $1.01 per share on revenue of $9.70 million. 
• scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) is projected to report quarterly loss at $0.39 per share on revenue of $12.18 million. 
• CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is likely to report earnings for its fourth quarter. 
• Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $8.89 million. 
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $559.67 million. 
• Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) is estimated to report quarterly loss at $0.41 per share on revenue of $3.88 million. 
• icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.50 million. 
• Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $9.87 million. 
• Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is projected to report quarterly loss at $0.24 per share on revenue of $15 thousand. 
• LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) is estimated to report earnings for its fourth quarter. 
• North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) is estimated to report quarterly earnings at $1.17 per share on revenue of $318.60 million. 
• Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) is likely to report quarterly loss at $0.58 per share on revenue of $2.47 million. 
• Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $732.00 million. 
• Prudential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUK#NYSE">PUK</a>) is expected to report earnings for its Fiscal Year 2024. 
• Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $4.94 million. 
• FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) is expected to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

CAAP

CAPR

CWEB

EPSN

FIVE

GROY

ICAD

JILL

LENZ

LQDA

OLLI

PGEN

PRSO

SCPH

SERA

SRAD

SWKH

TISI

TWFG

Earnings Scheduled For March 19, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>William Blair analyst Andy Hsieh initiated coverage on Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Perform rating. Altimmune shares closed at $6.42 on Thursday. <a href="https://www.benzinga.com/quote/alt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Chase Knickerbocker initiated coverage on MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy rating and announced a price target of $39. MediWound shares closed at $16.23 on Thursday. <a href="https://www.benzinga.com/quote/mdwd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Faiza Alwy initiated coverage on CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Buy rating and announced a price target of $89. CoStar Group shares closed at $74.36 on Thursday. <a href="https://www.benzinga.com/quote/csgp/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy rating and announced a price target of $42. Summit Therapeutics shares closed at $18.49 on Thursday. <a href="https://www.benzinga.com/quote/smmt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Yasmeen Rahimi initiated coverage on Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) with an Overweight rating and announced a price target of $48. Avalo Therapeutics shares closed at $6.60 on Thursday. <a href="https://www.benzinga.com/quote/avtx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>

Initiation

AVTX

CSGP

SMMT

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Craig-Hallum analyst Chase Knickerbocker initiates coverage on MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy rating and announces Price Target of $39.

Craig-Hallum Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $39

MediWound Initiates VALUE Global Phase III Trial Of EscharEx In Treatment Of Venous Leg Ulcers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital raised the price target for Autodesk, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $287 to $308. BMO Capital analyst Daniel Jester maintained a Market Perform rating. Autodesk shares closed at $317.96 on Tuesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) from $25 to $18. Baird analyst Mark Altschwager downgraded the stock from Outperform to Neutral. Kohl&#8217;s shares closed at $15.22 on Tuesday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) price target from $15 to $17. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Iris Energy shares settled at $9.56 on Tuesday. <a href="https://www.benzinga.com/quote/IEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group boosted The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $62 to $85. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Kroger shares closed at $60.57 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised New Jersey Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) price target from $46 to $49. Guggenheim analyst Shahriar Pourreza maintained a Neutral rating. New Jersey Resources shares closed at $50.71 on Tuesday.  <a href="https://www.benzinga.com/quote/NJR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets boosted MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) price target from $80 to $100. Northland Capital Markets analyst Mike Grondahl maintained an Outperform rating on the stock. MoneyLion shares closed at $86.64 on Tuesday. See how other analysts view this stock.</li>
<li>Benchmark cut the price target for H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) from $53 to $48. Benchmark analyst Fawne Jiang maintained a Buy rating. H World shares settled at $33.10 on Tuesday. <a href="https://www.benzinga.com/quote/HTHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup boosted Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) price target from $42 to $59. Citigroup analyst Paul Lejuez upgraded the stock from Neutral to Buy. Urban Outfitters shares closed at $40.14 on Tuesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut the price target for MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) from $28 to $25. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. MediWound shares closed at $16.90 on Tuesday. <a href="https://www.benzinga.com/quote/MDWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) price target from $80 to $90. Needham analyst Mike Cikos maintained a Buy rating. Nutanix shares closed at $72.35 on Tuesday. <a href="https://www.benzinga.com/quote/NTNX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42210452/top-3-consumer-stocks-that-are-set-to-fly-in-q4">Top 3 Consumer Stocks That Are Set To Fly In Q4</a></li>
</ul>

Pre-Market Outlook

ADSK

HTHT

IREN

NTNX

Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and lowers the price target from $28 to $25.

HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $25

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.45) by 117.78 percent. The company reported quarterly sales of $4.36 million which missed the analyst consensus estimate of $6.01 million by 27.49 percent. This is a 8.81 percent decrease over sales of $4.78 million the same period last year.

MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is projected to report quarterly loss at $0.08 per share on revenue of $708 thousand. 
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $164.00 million. 
• Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is expected to report quarterly loss at $0.29 per share on revenue of $194.49 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $9.63 billion. 
• Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $3.71 billion. 
• JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) is estimated to report quarterly earnings at $2.51 per share on revenue of $2.26 billion. 
• Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is expected to report quarterly earnings at $2.69 per share on revenue of $3.03 billion. 
• Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is projected to report quarterly earnings at $1.64 per share on revenue of $2.41 billion. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $675.30 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $276.88 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $26.70 million. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is estimated to report earnings for its third quarter. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.72 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $2.56 billion. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is estimated to report quarterly earnings at $0.69 per share on revenue of $933.86 million. 
• Cadeler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDLR#NYSE">CDLR</a>) is likely to report earnings for its third quarter. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $1.18 billion. 
• American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is projected to report quarterly earnings at $2.37 per share on revenue of $458.29 million. 
• Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is projected to report earnings for its third quarter. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is projected to report quarterly loss at $0.44 per share on revenue of $6.01 million. 
<h3>Companies Reporting After The Bell</h3>
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $562.00 million. 
• Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $54.75 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is expected to report quarterly loss at $0.09 per share on revenue of $113.65 million. 
• Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $747.44 million. 
• Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) is projected to report quarterly loss at $0.21 per share on revenue of $30.59 million. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $1.34 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $3.35 billion. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $983.03 million. 
• Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) is estimated to report quarterly earnings at $2.06 per share on revenue of $24.72 billion. 
• Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $572.16 million. 
• Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is expected to report quarterly loss at $0.92 per share on revenue of $58.91 million. 
• Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is likely to report quarterly earnings at $2.12 per share on revenue of $1.56 billion. 
• Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) is projected to report quarterly earnings at $1.76 per share on revenue of $2.13 billion. 
• Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $79.03 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is likely to report earnings for its third quarter. 
• Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its third quarter. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $116.39 million. 
• HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is expected to report quarterly earnings at $0.93 per share on revenue of $14.00 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBA

AMWD

ARWR

BURL

CDLR

CRWD

DELL

EMBC

ICCM

MANU

NOAH

PNST

TITN

WDAY

Earnings Scheduled For November 26, 2024

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MediWound to report an earnings per share (EPS) of $-0.44.
The announcement from MediWound is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.24 in the last quarter, leading to a 4.01% increase in the share price on the following day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.41</td>
<td>-0.23</td>
<td>-0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-0.39</td>
<td>-0.19</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550447_0.png" alt="eps graph" />
<h3>Performance of MediWound Shares</h3>
Shares of MediWound were trading at $16.48 as of November 22. Over the last 52-week period, shares are up 96.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: MediWound

Press Releases

MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Report First Quarter 2025 Financial Results

Biotech

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

MediWound

Noticias

Últimas noticias sobre MediWound (NASDAQ:MDWD) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL